Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a registered ... common and aggressive adult brain cancer—announced today the appointments of its first Senior ... with supporting the organization’s initiatives and overall vision. , "Senior Fellows are more ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
(Date:6/23/2020)... ... 2020 , ... The field of quantitation of large molecules or proteins has ... area. However, the use of mass spectrometry in this field has gained a lot ... do you choose which approach to use (LBA or MS)?” In many cases, ...
Breaking Biology News(10 mins):
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed ... Manager Regulatory Solutions, in a one hour live webinar on Thursday, August ... in China for drugs and medical devices. Specifically, for medical devices, the NMPA has ...
(Date:7/18/2020)... , ... July 16, 2020 , ... ... to aid in the early detection and prevention of high-burden diseases, and Centric ... US-based hospitals and healthcare organizations to utilize existing data in order to identify ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in ... the patient's condition, treatment may be offered IV, intrathecal or with a combination. , ... dementia, and the incidence continues to increase as individuals live longer. There is no ...
Breaking Biology Technology: